Heparan sulfate levels in mucopolysaccharidoses and mucolipidoses
- 13 December 2004
- journal article
- research article
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 28 (5) , 743-757
Abstract
Summary: Glycosaminoglycans are accumulated in both mucopolysaccharidoses (MPS) and mucolipidoses (ML). MPS I, II, III and VII and ML II and ML III patients cannot properly degrade heparan sulphate (HS). In spite of the importance of HS storage in the metabolic pathway in these diseases, blood and urine HS levels have not been determined systematically using a simple and economical method. Using a new ELISA method using anti‐HS antibodies, HS concentrations in blood and urine were determined in MPS and ML II and ML III patients. HS concentrations were determined in 156 plasma samples from MPS I (n = 23), MPS II (n = 26), MPS III (n = 24), MPS IV (n = 62), MPS VI (n = 5), MPS VII (n = 5), ML II (n = 8) and ML III (n = 3), and 205 urine samples from MPS I (n = 33), MPS II (n = 33), MPS III (n = 30), MPS IV (n = 82), MPS VI (n = 7), MPS VII (n = 9), ML II (n = 8) and ML III (n = 3). The ELISA method used monoclonal antibodies against HS. MPS I, II, III and VII and ML II and III patients had significant elevation in plasma HS, compared to the age‐matched controls (p < 0.0001). Eighty‐three out of 89 (93.3%) of individual values in the above MPS types and ML were above the mean +2SD of the controls. In urine samples, 75% of individual values in patients with those types were above the mean +2SD of the controls. In contrast to the previous understanding of the HS metabolic pathway, plasma HS levels in all five MPS VI and 15% of MPS IV patients were elevated above the mean +2SD of the controls. These findings suggest that HS concentration determined by ELISA, especially in plasma, could be a helpful marker for detection of the most severe MPS I, II, III, VI and VII and ML II, distinguishing them from normal populations.Keywords
This publication has 22 references indexed in Scilit:
- Newborn Screening for Lysosomal Storage Disorders: Clinical Evaluation of a Two-Tier StrategyPediatrics, 2004
- Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)The Journal of Pediatrics, 2004
- Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human α-L-iduronidase (laronidase)The Journal of Pediatrics, 2004
- Glycosaminoglycan degradation fragments in mucopolysaccharidosis IGlycobiology, 2004
- Determination of monosaccharides and disaccharides in mucopolysaccharidoses patients by electrospray ionisation mass spectrometryMolecular Genetics and Metabolism, 2003
- Analytical method of chondroitin/dermatan sulfates using high performance liquid chromatography/turbo ionspray ionization mass spectrometry: application to analyses of the tumor tissue sections on glass slidesBiomedical Chromatography, 2001
- 10E4 Antigen of Scrapie Lesions Contains an Unusual Nonsulfated Heparan MotifJournal of Biological Chemistry, 2001
- Glycosaminoglycan Accumulation and Excretion in the Mucopolysaccharidoses: Characterization and Basis of a Diagnostic Test for MPSMolecular Genetics and Metabolism, 1998
- Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI.Journal of Clinical Investigation, 1997
- Presence of N-Unsubstituted Glucosamine Units in Native Heparan Sulfate Revealed by a Monoclonal AntibodyJournal of Biological Chemistry, 1995